Abstract Individuals diagnosed with specific
Introduction
Prostate cancer is the second leading cause of cancerrelated deaths among United States males and the most commonly diagnosed malignancy in this country. In 2008, it is estimated that over 28,000 men would die of this disease in the United States [1] . Patients with organ-confined prostate cancer can be effectively treated through radical prostatectomy or radiation therapies; however, most invasive tumors of the prostate are completely resistant to general cytotoxic therapies [2, 3] . As such, the mainline therapeutic intervention for disseminated disease is androgen deprivation therapy (ADT), which relies on the androgen dependence of this tumor type [4] [5] [6] . ADT is initially effective, as almost all patients undergo a period of remission, manifested by tumor cell death and reduced tumor burden. However, the majority of patients develop ADT-resistant tumors, for which no effective or curative treatment has been identified [7] . Therefore, identifying the factors that influence ADT efficacy is imperative to improve the outcome of prostate cancer treatment and increase patient survival of this deadly disease.
ADT is designed to ablate androgen receptor (AR) function. AR is a nuclear hormone receptor and functions as a ligand-dependent transcription factor. Androgen (testosterone and the high affinity dihydrotestosterone, DHT) binds to AR and stimulates receptor homodimerization and rapid translocation to the nucleus. Activated nuclear AR binds to androgen response elements (AREs) in the promoter regions of target genes and recruits co-activator molecules to initiate gene transcription. Activation of AR results in numerous biological outcomes, dependent on cellular context, including secretion of key proteases and cellular proliferation. Hence, ADT aims to inhibit cellular proliferation by preventing AR activity either through the use of direct AR antagonists or through the inhibition of ligand (androgen) synthesis (Fig. 1a) . At the cellular level, ADT triggers a cascade of events leading to either programmed cell death or cell cycle arrest. Clinically, efficacy of ADT is demonstrated by tumor remission; however, recurrent ADT-resistant tumors typically arise within a median of 2-3 years [7] . Development of ADT-resistance is attributed to restored AR activity and consequential resumption of tumor growth. Several molecular mechanisms have been identified and linked to AR reactivation within ADT-resistant tumors. In up to an estimated 25% of therapy-resistant tumors, ADT is known to select for mutations of the AR ligand binding domain that alters the conformation of this domain and allows binding and activation by other steroid hormones (e.g., estrogen, cortisol, progesterone) or even therapeutic AR antagonists (e.g., flutamide) [8] [9] [10] [11] . Other examples of alteration in AR action include AR overexpression, ligand-independent AR activation, or overexpression of AR co-activators [reviewed in 12] . Given the biological requirement of AR activation for prostate adenocarcinoma cell growth, it is evident that mechanisms of enhancing AR action can have substantial effects on prostate cancer development and treatment.
Several environmental and industrial compounds demonstrate the potential to mimic, alter, or block endogenous hormone action and are generally identified as endocrineactive compounds. There is an increased interest in elucidating their biological effects and impacts on human health. Several endocrine-active compounds have been hypothesized to alter androgen action and/or reproductive organ growth and development, including the prostate. Most notably, some studies have suggested that in utero or neonatal exposure to compounds such as bisphenol A (BPA), polychlorinated biphenyls (PCBs), or hexachlorobenzene (HCB) increases prostate size or weight, thus suggesting that these agents could influence early growth patterns [13] [14] [15] [16] [17] [18] . Recent bioassays have shown that developmental exposure to BPA increases susceptibility to prostate cancer in adult rats [19] [20] [21] , and numerous studies have demonstrated the adverse effect of BPA on prostatic cell proliferation and architecture [14, 15, 18, 22, 23] . However, a uniform understanding of endocrine-active compounds on prostate development and cancer incidence has yet to be fully elucidated, and many observations remain highly controversial. Several recent publications review the relationship between BPA exposure and prostate disease [24] [25] [26] [27] .
Recent reports have highlighted a novel interaction between specific endocrine-active compounds and select prostate tumor-derived mutant ARs. It has been shown that environmental compounds, such as BPA (1 nM) and dichlorodiphenyldichloroethylene (DDE; 10 pM), can activate tumor-derived mutant ARs and induce AR-dependent proliferation of the cancer cell in the absence of natural mitogenic stimulus [28] [29] [30] . These studies shift the attention from compounds causing, or increasing the susceptibility to, prostate cancer to assessing the impact of these agents on the progression and treatment of established disease. These data suggest that although a prostate cancer patient may be using pharmacologic means to reduce AR action, the presence of endocrine-active compounds may be reducing the efficacy of therapy by inducing proliferation of the cancerous cells. It is essential to define the relative risk of environmental exposure to endocrine-active compounds in patients undergoing ADT for prostate cancer. These analyses may impact the human health risk assessments for such compounds, as highly susceptible subpopulation of humans may be identified and necessitate consideration for environmental risk management. Herein, we will evaluate the hypothesis that BPA may negatively impact the success of prostate cancer ADT, including a discussion of BPA exposure levels, a description of the hypothesized mode of action, and the overall likelihood that BPA may be a health concern for prostate cancer patients and disease management.
Bisphenol A exposure
Bisphenol A (BPA) is an industrial non-planer compound used as a component of polycarbonate plastics, epoxy resins, and dental sealants [31] . The epoxy resins are used as coatings for food cans and metal jar lids, as general protective coatings, finishes, adhesives, and as coatings for PVC pipes. The polycarbonate plastics are used in compact disk manufacturing, household appliances, food packaging, and plastic bottles with high impact strength, hardness, and toughness. Due to the vast increase in BPA-containing products (notably polycarbonate plastics), manufacture of and exposure to BPA has dramatically increased in the United States within the past decade [32] . Currently, onethird of all BPA is manufactured in the United States, estimated close to 1.1 9 10 6 metric tons (over 1,100 million kg) annually [32] .
Due to the widespread use of BPA, the potential for human exposure is significant. Most human exposure to BPA comes from contamination in food caused by migration from containers made with BPA [reviewed in 31, 33] . BPA has been detected in canned vegetables, fish, meat, diary, and infant formula [34] [35] [36] . Several studies have detected migrated BPA levels between 2 and 87 ng/ml following heating of cans to temperatures used in the processes of canning food [reviewed in 31]. BPA migration can also be affected by the storage time of canned foods, and migration from can coatings may differ between manufacturing plants and methods and/or types of internal coating materials. BPA migration from polycarbonate Fig. 1 a Schematic illustrating the molecular action of androgen and the impact of standard prostate cancer therapies in a prostatic adenocarcinoma cell. Androgen from the blood stream is able to diffuse into the prostatic epithelial cell where it is converted to dihydrotestosterone (DHT) by the enzymatic action of 5-a-reductase. DHT is a high affinity ligand for the androgen receptor (AR), which upon ligand binding, is disassociated from heat shock proteins (HSP) in the cytoplasm of the cell. Ligand bound AR undergoes conformational changes, dimerizes and then translocates into the cell nucleus. Once inside the nucleus, with the assistance of co-activator molecules, AR binds to target gene regulatory regions (ARE's: androgen response elements) such as prostate specific antigen (PSA). AR transcriptional targets control cellular function such as proliferation and secretion. Standard therapies for prostate cancer are aimed towards inhibiting the signaling of androgen and AR. Androgen deprivation therapy (ADT) uses compounds such as gonadotropin releasing hormone (GnRH) agonist to inhibit the synthesis of testosterone. Direct AR antagonists, such as bicalutamide, bind to AR and cause transcriptional repression. Both methods of ADT prevent AR-dependent proliferation. b Illustration of the impact of bisphenol A (BPA) on androgen receptor signaling. Due to the selective pressure of ADT, mutant ARs arise that are amenable to activation by alternate ligands, such as BPA. BPA binds to mutant ARs (e.g., AR-T877A), causing release from heat shock proteins, dimerization and translocation into the nucleus. BPA bound AR-T877A binds to androgen responsive elements and induce transcription of target genes, leading to cellular proliferation. Additionally, there is a putative link between BPA cellular effects and the estrogen receptor beta (ERb) signaling within a prostate epithelial cell. At this point, it is unknown whether ERb and AR function together to drive proliferation, or if activated ERb can elicit proliferation on its own. It is known that activation of mutant AR is a necessary event preceding BPA-mediated proliferation. In the presence of ADT, BPA is able to induce cellular proliferation and potential therapeutic bypass for prostate cancer cells plastics has also attracted much public attention. Several studies have showed relatively low levels of BPA leaching from new polycarbonate bottles; however, levels were up to 10-fold higher from used and/or scratched bottles [37] . It is believed that due to degradation of the plastic polymers, BPA elution is increased with age and wear. The carbonate linkages between polymers are initially stable, but can hydrolyze upon exposure to hot water or alkaline pH, leading to migration of BPA from plastics after washing and sterilization, as well as with general wear and use [31] .
There have been numerous attempts to identify the amount and extent of BPA exposure to the human population. A recent study by Calafat et al. [38] found that up to 95% of their demographically diverse sample of the United States adult population had detectable BPA in their urine, with concentrations reported to range in the nanomolar range (mean concentration in urine of 1.33 lg/l). Additionally, several other studies have reported adult BPA levels in the nanomolar range (using both serum and urine analyses), with nearly 100% of sample populations having detectable BPA or BPA metabolites [reviewed in 39] .
Several attempts at calculating the daily exposure levels of BPA have been made. Although diverse in geographical location, sample size and demographics, and method of calculation, all estimates are relatively consistent. On the basis of several congruent studies, the daily intake of BPA can be assumed to be \1 lg/kg body weight/day [31] . Given the increasing usage of BPA and the body of literature that has quantified BPA in human serum and/or urine, it is plausible that the majority of adult males in the United States are exposed to detectable amounts of BPA. Therefore, it is a legitimate concern as to whether BPA has adverse affects on prostate cancer management and treatment efficacy, at doses that the average adult male may encounter.
Bisphenol A impact on prostate cancer treatment: in vivo evidence
There is currently no human epidemiological or clinical studies assessing the impact of endocrine disruptive compounds, such as BPA, on prostate cancer management; however, recent murine in vivo studies directly examined the impact of low dose (within the range reported in human serum) BPA on prostate cancer disease progression and treatment. There is a paucity of experimental models with which to study prostate cancer; however, the LNCaP xenograft tumor model closely mimics standard disease progression and ADT cellular processes. LNCaP cells are one of the few human prostate cancer cell lines that retain the characteristics of early stage disease; they are androgen responsive and retain AR expression [40, 41] . Importantly, the LNCaP cell line harbors a BPA-responsive mutant AR, AR-T877A [29] . The most common mutational ''hot spot'' of the AR lies within the ligand binding domain, containing codon 877. Not only has it been estimated that up to 25% of advanced disease harbors mutant AR, Gaddipati et al. [42] determined that codon 877 mutations are the most frequent mutations detected in advanced prostate cancer. This provides strong support for the relevance and applicability of the LNCaP model to study the impact of BPA on prostate cancer treatment. Briefly, male nude mice were subcutaneously injected with LNCaP cells [43] . Once tumors formed on the flanks of the male mice, mice were castrated to deplete endogenous androgen and mimic ADT. Mice were then randomized into two cohorts, one receiving subcutaneous placebo time-release pellets and the other receiving subcutaneous BPA 21-day time-release pellets. These pellets were manufactured with 12.5 mg of BPA and through serum analysis, it was shown that the presence of these pellets resulted in a continual release of BPA into the mouse circulatory system, steadily declining from approximately 27-2 ng/ml over 28 days. This methodology has the caveat that human exposure to BPA is primarily through oral ingestion, and therefore, BPA goes through first pass metabolism in the liver, where it is estimated that 95% of ingested BPA is metabolized to the glucocoronidated form (BPA-monoglucuronide, BPAG). BPAG has been found to contain no endocrine disrupting or adverse effects [44, 45] . Wetherill et al. [43] did not measure BPAG levels in serum; however, the level of BPA in the serum of mice implanted with the time-release pellets did fall within the range of BPA detected in adult human serum. This methodology, however, still leaves some uncertainty to the effect of the route of administration and increases the uncertainty for direct correlation to the human paradigm of BPA exposure. Conversely, this methodology reduces the uncertainty concerning rodent versus human metabolic processing of BPA, and assumes that since the concentration of free BPA in the blood fell within the range reported in humans, the human prostatic xenograft would be exposed to equivalent levels of BPA as a human prostatic tumor.
The salient observation of Wetherill et al. [43] was that low levels of BPA had a negative impact on the disease progression and efficacy of therapy in the murine xenograft model of prostate cancer. The environmentally relevant levels of BPA during mimicked ADT in the mice, resulted in an increase in a AR target gene product (prostate specific antigen, PSA), larger xenograft tumor volumes, increased cellular proliferation in the tumors, and a shorter time to therapy failure compared to placebo controls. The implications of this finding for the human population are significant, given the inevitable and short time to therapy failure and no effective therapeutic strategies for advanced disease. These reports provide the impetus to fully examine whether exogenous compounds could negatively interfere with prostate cancer treatment and disease management.
Bisphenol A impact on prostate cancer treatment: mode of action
There is in an vitro evidence indicating plausible modes of action of BPA-mediated reduced therapeutics efficacy for prostate cancer [28] [29] [30] . Multiple lines of evidence indicate that the key event resulting in BPA-facilitated therapeutic bypass of prostate cancer cells is the binding to and activation of tumor-derived mutant ARs by BPA, resulting in BPA:AR complex-mediated cellular proliferation [28] [29] [30] 46] .
Human prostate cancer cell lines were used to study the mechanism by which BPA impacted prostate cancer progression. Upon androgen withdrawal (switching the cells to culture conditions deprived of steroid hormones), LNCaP cells undergo growth arrest in G0; however, cell cycle can be re-initiated and regulated by adding mitogenic levels of androgen. Therefore, the ability of BPA to activate an endogenous AR within the molecular context of human prostate cancer cells was tested in this tissue culture system. When BPA was added to these cells in the absence of steroid hormones, BPA facilitated cell cycle entry and androgen-independent proliferation. The mitogenic capacity of BPA was shown to require AR-T877A activation; blocking the receptor with a pure antagonist diminished the proliferative response. Additionally, it was determined that the mitogenic dose response was biphasic or resulted in an ''inverted U'' dose response, typical of hormone and hormone receptor mediated proliferation, [47] and 10 -9 M (1 nM) was the optimal mitogenic dose of BPA. This finding is salient, as nanomolar concentrations of BPA are well within the estimated ranges of human exposure [39] , as detected in serum and urine samples. However, toxicokinetics and the exact tissue concentrations of BPA are not taken into account in this correlation, and further investigation of internal tissue dosimetry would greatly enhance this area of research.
In a further study, Wetherill et al. [28] explored the ability of BPA to activate additional mutant ARs. It was shown that AR-negative or wild-type AR expressing prostate cancer cells were refractory to BPA-mediated effects. Additionally, BPA was able to activate other tumor-derived AR mutants, thus expanding the potential influence of BPA on prostate cancer. Combined, these data begin to associate BPA as an inappropriate and effective mitogen for prostate cancer cells, whose mode of action is mediated through activation of tumor-derived mutant ARs, in the absence of endogenous, natural ligand (Fig. 1b) . These data support the hypothesis that endocrine-active compounds, such as BPA, could possibly contribute to therapeutic bypass in patients with advanced prostate cancer via mutant AR-mediated mitogenesis.
Although a link has been established between environmentally relevant levels of BPA and the bypass of standard ADT for prostate cancer using both in vivo and in vitro models, much effort needs to be focused on elucidating the exact mechanism of BPA action in prostate cancer cells. Activation of tumor-derived AR mutants has been identified as a key event; however, the precise mechanism of AR proliferative regulation is, itself, poorly understood. Experiments comparing the transcriptional signature profiles of BPA-treated and DHT-treated prostate cancer cells have attempted to elucidate the genetic mechanisms of BPA-mediated proliferation and have confirmed BPAmediated induction of AR target genes [46] . Interestingly, BPA treatment also resulted in downregulation of estrogen receptor beta (ERb), not seen with DHT [46] . This observation is significant because ERb is thought to be required for AR-mediated proliferation of androgen-dependent prostate cancer cells [48, 49] . A hypothesis emerges wherein low level BPA activates tumor-derived AR mutants, and through ill-defined mechanisms, decreases expression of ERb. Reduced ERb allows for enhanced proliferation of prostate cancer cells, even in the absence of androgen (Fig. 1b) . ERb has been shown to be important in prostate cancer disease progression, as numerous clinical observations of prostate cancer specimens show a clear reverse correlation between ERb levels and prostate cancer stage [50] [51] [52] [53] . Further work needs to be focused on examining both the molecular link between AR-mediated proliferation and ERb signaling, and the requirement of ERb for the adverse effects of BPA in the prostate.
In summary, significant evidence indicates that in the absence of androgen (i.e., during standard therapy for prostate cancer, ADT) environmentally relevant levels of BPA can bind and activate common tumor-derived AR mutants which is known to arise during prostate cancer disease progression. Activation of the AR results in ARdependent proliferation of prostate cancer cells, potentially converging on ERb signaling pathways. BPA-mediated proliferation may lead to bypass of ADT and reduced time to therapeutic failure, as demonstrated in murine xenograft tumor models. It remains plausible that exposure to BPA may have a detrimental impact on prostate cancer management (Fig. 2) . Clinically, options exist for remediation of ubiquitous exposure to BPA or other endocrine-active compounds in prostate cancer patients. Use of the direct AR antagonist, bicalutamide, results in the impediment of AR-mediated proliferation in the presence of BPA [28, 29] . Therefore, bicalutamide administration may effectively block this pathway. A shift in the clinical treatment paradigm toward increased use of direct AR antagonists (as opposed to targeting androgen synthesis pathways) would reduce the risk of endocrine-active compound-mediated therapy bypass. While it is clear that alternative strategies are needed to improve the survival outcome for patients with advanced stage prostate cancer, expanding the time to therapy failure and increasing the effectiveness of current treatment modalities would be well received by prostate cancer patients.
Future needs
The hypothesis that disease management may be negatively impacted by environmental exposure has important clinical and human health risk assessment implications. Conclusive evidence is still needed to fully define the impact of endocrine disrupting compounds, such as BPA, on prostate cancer disease management; additional rodent studies and epidemiology evaluation of human populations may provide further insights. Furthermore, toxicokinetic and physiologically based pharmacokinetic research would significantly enhance the understanding of internal dose response and target tissue dosimetry of BPA in the prostate.
Patient education about the dangers of exposure to environmental endocrine-active compounds can be increased through public health and community efforts. Not using old and/or worn plastic bottles, not leaving plastic drinking bottles in places of extreme heat (i.e., inside cars during high temperature days), not microwaving food in plastic containers and reducing canned food consumption are examples of measures that are reported as ways to reduce the prostate cancer patient's potential for BPA exposure. Increasing the awareness of compounds that may negatively interfere with standard therapy allows for the clinicians to prescribe more effective treatments and for the patients to improve the therapeutic effectiveness via simple lifestyle changes. Exposure to BPA represents an example of an environmental endocrine disruptor with possible interference of disease management, and it highlights the need for further investigation into the impact of Fig. 2 Diagram of the events leading to reduced therapeutic efficacy from exposure to environmental endocrine active compounds. When a patient first presents with prostate cancer, the adenocarcinoma cells express the wild type androgen receptor and are reliant upon androgen for mitogenic signaling. As such, androgen deprivation therapy (ADT) is utilized to exploit the dependence on androgen and adenocarcinoma cells undergo programmed cell death resulting in tumor remission. Ultimately however, the AR becomes somatically mutated and tumor growth is resumed. Cells expressing mutant ARs are potentially sensitized to select endocrine active compounds and are stimulated to grow and survive even in the absence of androgen. This cellular utilization of endocrine active compounds as mitogenic signals, may lead to exacerbated adenocarcinoma cell growth and a resistance to therapeutic options other endocrine-active compounds on hormone-regulated disease treatments.
Are other environmental contaminants inferring with disease management?
The question remains as to whether BPA interference with late-stage prostate cancer treatment is an anomaly or whether other environmental contaminants might negatively impact this and/or other disease management paradigms. It is well known that there are numerous ubiquitous compounds in the environment which are hypothesized to mimic estrogen action. It is unknown whether any of these may elicit similar proliferative responses within the context of tumor-derived AR mutant expression in prostate cancer cells.
An obvious analogy to the BPA and prostate cancer story is the situation of endocrine-active compounds and breast cancer treatment. Breast cancer treatment options are significantly different from prostate cancer operation; however, it is still a disease that is, at least simplistically, regulated via estrogen and the estrogen receptor (ER). Many molecular alterations have been identified in breast cancer cells, vastly increasing the molecular variability amongst patients. The standard therapeutic strategy for breast cancer entails the use of tamoxifen, a direct and potent ERa antagonist, which effectively blocks all ER signaling. As such, even the presence of estrogenic endocrine-active compounds would likely not be able to bypass the effects of tamoxifen [54] . However, due to the side effects (increased osteoporosis and incidence of uterine cancer) of tamoxifen use, there is a push to utilize other treatment strategies, such as aromatase inhibitors [55] [56] [57] . Aromatase inhibitors block the metabolism and formation of estrogen, thereby reducing the estrogenic signaling capacity or ER, however, leaving the ER intact and fully functional. This molecular context may enable estrogenic environmental compounds able to bind to and activate ERa. Particularly of importance, is the fact that often ERa expression is increased in breast cancer tumors [58] , so even so-called weak estrogenic endocrine disrupting compounds may be able to mediate a significant proliferative response in the absence of endogenous estrogen. Significantly, a recent study showed that environmentally low levels of BPA are able to interfere with chemotherapeutic agents in both ERa-positive and -negative breast cancer cell lines, possibly by increasing anti-apoptotic factors [59] .
Thyroid diseases, polycystic ovarian syndrome, and uterine cancer are examples of other diseases that are regulated by hormone action and treatment strategies often manipulate endocrine signaling. It is possible that clinical management and treatment of these diseases may also be amenable to influence by endocrine-active compounds in the environment. There may also be other drug targets or specific diseases that render patients more susceptible to environmental contaminants, which warrant further exploration into drug-environmental compound interactions and disease molecular state-environmental compound interactions.
The molecular changes that occur within organs due to either the presence of disease or the therapeutic strategies utilized are appreciated by molecular biologist, pharmacologist and clinicians. However, these specific molecular contexts are rarely challenged with environmental insult. Moreover, it is recognized that the efficacy of disease treatment is often less than would be estimated based on molecular biology. Certainly, population diversity and genetic polymorphisms account for the wide variation in the successful management of select diseases. However, it is also plausible that the presence of environmental compounds may be interfering with drug action and reducing the efficacy of therapy. Detailed and specific data on environment: disease-mediated molecular milieu may be valuable information for human health risk assessments, as patients may represent subpopulations of individuals more highly susceptible to specific environmental insult.
